[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"interstitial-fibrosis-if\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:interstitial-fibrosis-if":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":5},"100173415","proteogenomic-monitoring-and-assessment-of-kidney-transplant-recipients-100173415",false,"NCT01531257","Proteogenomic Monitoring and Assessment of Kidney Transplant Recipients","Mini-Kidney","Inclusion Criteria:\n\n1. Male and female recipients of all races, ≥18 years of age.\n2. Patients undergoing primary or subsequent deceased-donor or living donor kidney transplantation.\n3. Subject and\u002For guardian must be able to provide informed consent.\n4. Subject and\u002For guardian must be able to comply with the study protocol.\n\nExclusion Criteria:\n\n1. Need for combined organ transplantation with an extra-renal organ and\u002For islet cell transplant.\n2. Recipients of previous non-renal solid organ and\u002For islet cell transplantation.\n3. Infection with HIV.\n4. Inability or unwillingness of a participant and\u002For guardian to provide informed consent","ALL","18 Years",{"count":19,"type":20},1000,"ESTIMATED","OBSERVATIONAL","Chronic Allograft Nephropathy (CAN)\u002FInterstitial fibrosis and Tubular Atrophy (IFTA) is responsible for most kidney transplant failures. CAN\u002FIFTA on a 3 month kidney biopsy strongly predicts graft survival long term. CAN\u002FIFTA remains a vexing problem for clinicians because current monitoring tools, namely the serum creatinine concentration, are not sensitive to early changes in glomerular filtration rate (GFR) or to histologic damage.\n\nDespite advances in prevention of acute rejection (AR), it is still a significant and potentially devastating complication of solid organ transplantation. One strategy to reduce the risk of rejection is to perform kidney biopsies to detect subclinical acute rejection (SCAR) and treat to prevent progression to rejection. There is evidence that treating SCAR can prevent further immune mediated injury to the kidney, a precursor to CAN\u002FIFTA.\n\nKidney biopsies provide better information but are limited due to safety concerns, patient preference and cost issues. Better, early and less invasive markers of CAN\u002FIFTA will allow early intervention as well as improved graft and better patient outcomes.\n\nThis study seeks to validate specific proteogenomic biomarker panels for AR and CAN\u002FIFTA in a prospective blood, urine and kidney tissue monitoring study of kidney transplant recipients who will be scheduled for standard of care biopsies.",[24,25,26,27],"Acute Rejection (AR) of Transplanted Kidney","Chronic Allograft Nephropathy (CAN)","Interstitial Fibrosis (IF)","Tubular Atrophy (TA)","RECRUITING","2026-04-29",{"date":31,"type":32},"2026-05-05","ACTUAL",{"date":34,"type":4},"2010-04",{"date":36,"type":20},"2027-12",{"name":38,"class":39},"Northwestern University","OTHER"]